1 / 3

ALIMTA: Dosage and Administration

ALIMTA: Dosage and Administration. Reference: ALIMTA Summary of Product Characteristics (Eli Lilly, 2004). ALIMTA: Dosage and Administration. Reference: ALIMTA Summary of Product Characteristics (Eli Lilly, 2004). Dosing and administration: 1st-line treatment of NSCLC.

dragon
Download Presentation

ALIMTA: Dosage and Administration

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ALIMTA: Dosage and Administration Reference: ALIMTA Summary of Product Characteristics (Eli Lilly, 2004)

  2. ALIMTA: Dosage and Administration Reference: ALIMTA Summary of Product Characteristics (Eli Lilly, 2004).

  3. Dosing and administration: 1st-line treatment of NSCLC • The recommended dose of ALIMTA (pemetrexed for injection) is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with cisplatin 75 mg/m2 i.v. beginning 30 minutes after ALIMTA infusion. Myelosuppression is usually the dose-limiting toxicity with ALIMTA therapy. למידע מלא נא עיין בעלון לרופא כפי שאושר ע"י משרד הבריאות

More Related